Imagine a world where life-altering therapies for genetic disorders, cancer, and infectious diseases are not just a distant dream but a tangible reality, delivered precisely to the cells that need them most. RNA therapeutics hold this transformative promise, yet their potential remains locked
I'm thrilled to introduce Ivan Kairatov, a renowned biopharma expert with a wealth of experience in research and development, particularly at the intersection of technology and innovation in healthcare. With a deep understanding of how cutting-edge tools like artificial intelligence are reshaping
Imagine a world where aspiring surgeons can hone their skills without the constant presence of an expert mentor, receiving precise, real-time feedback as they practice critical techniques like suturing. This scenario is no longer a distant dream but a reality being shaped by an innovative AI-driven
Imagine a hidden ecosystem within the human body, teeming with trillions of microorganisms that quietly shape health, digestion, and even mood. This delicate gut microbiome, a cornerstone of well-being, faces an invisible yet pervasive danger: chemical pollutants. From pesticides on produce to
Rising demand, tighter budgets, and complex patients have pushed cardiovascular imaging from supporting act to central protagonist, and that shift is on full display in Vienna as echo, CMR, CT, and nuclear cardiology share one stage from December 11–13. Congress organizers set a clear purpose:
Every three minutes somewhere in the world, a person with type 1 diabetes calculates a dose of insulin and still lives with the nagging reality that even perfect math will not reproduce the split-second precision of native β-cells. Clinicians point to the autoimmune destruction that erased those
